Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.
Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.
复制标题
DOI：
10.3390/jpm11040296
复制
发表时间：
2021-04-13
影响因子：
--
通讯作者：
Lumniczky K
中科院分区：
文献类型：
--
作者：
Balázs K;Antal L;Sáfrány G;Lumniczky K
前列腺癌是世界上最常见的男性癌症之一。尽管有多种治疗方案可用于治疗，但它通常在晚期被发现为转移性疾病。前列腺癌筛查的基础是对前列腺大小和血液中前列腺特异性抗原（PSA）水平的体格检查，以及对疑似病例的活检。然而，这些标志物往往不能正确识别癌症的存在，或者它们的阳性可能导致过度诊断和随后的过度治疗，否则沉默的无进展的疾病。此外，这些标志物对于治疗反应或治疗相关毒性的个体风险的预测价值非常有限。因此，需要新颖的、最佳液体活检（血液来源）标记物或标记板，它们比目前日常使用的标记物具有更好的预后和预测价值。本文综述了循环肿瘤细胞、细胞外囊泡及其microRNA含量，以及细胞和可溶性免疫和炎症相关血液标志物在前列腺癌诊断、预后和治疗反应预测中的作用。特别强调的是预测放射治疗反应和放射治疗相关的晚期副作用的标志物。
Prostate cancer is among the most frequent cancers in men worldwide. Despite the fact that multiple therapeutic alternatives are available for its treatment, it is often discovered in an advanced stage as a metastatic disease. Prostate cancer screening is based on physical examination of prostate size and prostate-specific antigen (PSA) level in the blood as well as biopsy in suspect cases. However, these markers often fail to correctly identify the presence of cancer, or their positivity might lead to overdiagnosis and consequent overtreatment of an otherwise silent non-progressing disease. Moreover, these markers have very limited if any predictive value regarding therapy response or individual risk for therapy-related toxicities. Therefore, novel, optimally liquid biopsy-based (blood-derived) markers or marker panels are needed, which have better prognostic and predictive value than the ones currently used in the everyday routine. In this review the role of circulating tumour cells, extracellular vesicles and their microRNA content, as well as cellular and soluble immunological and inflammation- related blood markers for prostate cancer diagnosis, prognosis and prediction of therapy response is discussed. A special emphasis is placed on markers predicting response to radiotherapy and radiotherapy-related late side effects.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-08-0738
发表时间：
2008-07-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Caruso DJ;Carmack AJ;Lokeshwar VB;Duncan RC;Soloway MS;Lokeshwar BL
通讯作者：
Lokeshwar BL
影响因子：
29.7
作者：
Brubaker SW;Bonham KS;Zanoni I;Kagan JC
通讯作者：
Kagan JC
影响因子：
16
作者：
Bijnsdorp IV;Geldof AA;Lavaei M;Piersma SR;van Moorselaar RJ;Jimenez CR
通讯作者：
Jimenez CR
影响因子：
6.4
作者：
Brase, Jan C.;Johannes, Marc;Sueltmann, Holger
通讯作者：
Sueltmann, Holger
影响因子：
--
作者：
Chaiswing L;Weiss HL;Jayswal RD;Clair DKS;Kyprianou N
通讯作者：
Kyprianou N